Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetylcysteine + silibinin
- Development stage
- Unknown
- Lead developer
- UT Health San Antonio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
N-acetylcysteine + silibin is a combination of two antioxidant nutritional supplements being investigated for the treatment of diabetic nephropathy in patients with Type 2 Diabetes Mellitus (T2DM). N-acetylcysteine (NAC) serves as a precursor to glutathione, a critical endogenous antioxidant, while silibin (silibinin) is a flavonolignan derived from milk thistle (Silybum marianum) that exhibits potent antioxidant and anti-inflammatory properties. In clinical studies, silibin is often formulated as a phosphatidylcholine complex (Siliphos) to improve its oral bioavailability. The combination is designed to target oxidative stress and inflammation pathways, aiming to reduce proteinuria and systemic markers of kidney damage. This therapeutic regimen is being evaluated in Phase 2 clinical trials sponsored by the VA Office of Research and Development.
- Brand names
- Siliphos
- Other names
- N-acetylcysteine + silibinNAC + silibinN-acetylcysteine + silibininNAC + silibininN-acetylcysteine + Siliphos
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on acetylcysteine + silibinin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetylcysteine + silibinin.